Stem Cell Therapeutics Strengthens CD47 Franchise With Acquistion of Complementary Antibody Program

The technology was developed by scientists at the . SIRPa is the ligand of CD47, a molecule upregulated on many hematological and solid tumors.

http://www.hispanicbusiness.com/2013/10/17/stem_cell_therapeutics_strengthens_cd47_franchise.htm